Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orthofix Medical (OFIX) Change in Account Payables (2016 - 2025)

Historic Change in Account Payables for Orthofix Medical (OFIX) over the last 15 years, with Q3 2025 value amounting to $3.5 million.

  • Orthofix Medical's Change in Account Payables rose 18990.45% to $3.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $147000.0, marking a year-over-year increase of 10210.72%. This contributed to the annual value of -$5.6 million for FY2024, which is 16446.42% down from last year.
  • Latest data reveals that Orthofix Medical reported Change in Account Payables of $3.5 million as of Q3 2025, which was up 18990.45% from -$6.6 million recorded in Q2 2025.
  • Orthofix Medical's Change in Account Payables' 5-year high stood at $7.2 million during Q4 2021, with a 5-year trough of -$6.7 million in Q2 2024.
  • Moreover, its 5-year median value for Change in Account Payables was -$820000.0 (2024), whereas its average is $207894.7.
  • Per our database at Business Quant, Orthofix Medical's Change in Account Payables plummeted by 530357.14% in 2021 and then soared by 58041.49% in 2022.
  • Orthofix Medical's Change in Account Payables (Quarter) stood at $7.2 million in 2021, then tumbled by 123.12% to -$1.7 million in 2022, then skyrocketed by 362.88% to $4.4 million in 2023, then surged by 31.95% to $5.8 million in 2024, then plummeted by 40.0% to $3.5 million in 2025.
  • Its Change in Account Payables was $3.5 million in Q3 2025, compared to -$6.6 million in Q2 2025 and -$2.5 million in Q1 2025.